Highest Development Phases Marketed Precursor cell lymphoblastic leukaemia-lymphoma Phase III Non-Hodgkin's lymphoma Phase I/II Cancer Preclinical Multiple myeloma Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer
Most Recent Events 14 Aug 2018 CASI Pharmaceuticals expects that the CFDA will complete the review of Marqibo’s import drug clinical trial application within the next four to six months 24 Jun 2018 Biomarkers information updated 26 May 2017 Phase II development for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.